^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia

Published date:
11/06/2019
Excerpt:
Baseline mutations in the individual RTK pathway genes of NRAS and PTPN11, and in the RTK pathway genes as a group (defined in this analysis as NRAS, KRAS, PTPN11, KIT, and FLT3), were associated with a significantly lower likelihood of achieving a best response of CR or CRh with ivosidenib (P = .004, P = .016, and P < .001, respectively; Fisher’s exact test; Figure 2B), suggesting a role in primary treatment resistance. 
DOI:
https://doi.org/10.1182/bloodadvances.2020001503
Trial ID: